KYMR · Insider Trading
Kymera Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by KYMR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Nello Mainolfi | Chief Executive Officer | MIXED | — | −$3.35M |
| 2026-09-04 | Brian Adams | Chief Legal Officer | Sell | −6,371 | −$744.30K |
| 2026-07-27 | Terence Rooney | Chief Medical Officer | A | +38,000 | — |
| 2026-07-07 | Nello Mainolfi | Chief Executive Officer | MIXED | — | −$5.85M |
| 2026-07-02 | Noah Goodman | Chief Business Officer | Sell | −3,389 | −$387.33K |
| 2026-07-02 | Nello Mainolfi | Chief Executive Officer | MIXED | — | −$9.06M |
| 2026-07-02 | Bruce Booth | Director | Sell | −76,650 | −$8.28M |
| 2026-07-02 | Bruce N. Jacobs | Chief Financial Officer | MIXED | −15,731 | −$8.54M |
| 2026-06-26 | BIOTECHNOLOGY VALUE FUND II LP | Director | Sell | −16,306,580 | −$1.74B |
| 2026-06-25 | Gorjan Hrustanovic | Director | A | +6,068 deriv. | — |
| 2026-06-25 | Elena Ridloff | Director | A | +6,068 deriv. | — |
| 2026-06-25 | Jeffrey W. Albers | Director | A | +6,068 deriv. | — |
| 2026-06-25 | Victor Sandor | Director | A | +6,068 deriv. | — |
| 2026-06-25 | John Maraganore | Director | A | +6,068 deriv. | — |
| 2026-06-25 | Pamela Esposito | Director | A | +6,068 deriv. | — |
| 2026-06-25 | Noah Goodman | Chief Business Officer | MIXED | — | −$464.75K |
| 2026-06-25 | Bruce Booth | Director | A | +6,068 deriv. | — |
| 2026-06-25 | Baker Bros. Advisors (GP) LLC | Director | A | +72,816 deriv. | — |
| 2026-06-25 | Bruce Booth | Director | Sell | −285,684 | −$34.81M |
| 2026-06-25 | Bruce Booth | Director | Sell | −398,765 | −$43.99M |
| 2026-06-25 | BVF II GP LLC | Director | A | — | — |
| 2026-06-22 | Noah Goodman | Chief Business Officer | MIXED | — | −$194.88K |
| 2026-06-22 | Bruce Booth | Director | MIXED | −466,457 | −$45.06M |
| 2026-06-22 | Bruce Booth | Director | Sell | −31,798 | −$3.30M |
| 2026-06-03 | Bruce N. Jacobs | Chief Financial Officer | M | +12,653 | +$26.32K |
| 2026-05-27 | Jeremy G Chadwick | Chief Operating Officer | Sell | −17,184 | −$1.37M |
| 2026-05-19 | Bruce N. Jacobs | Chief Financial Officer | M | +15,000 | +$31.20K |
| 2026-05-19 | Pamela Esposito | Director | M | +1,000 | +$31.20K |
| 2026-05-11 | Elena Ridloff | Director | MIXED | — | −$167.40K |
| 2026-04-29 | Nello Mainolfi | Chief Executive Officer | MIXED | — | −$2.37M |
| 2026-04-24 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | −$15.28K |
| 2026-04-24 | Bruce Booth | Director | MIXED | −100 | −$454.60K |
| 2026-04-16 | Noah Goodman | Chief Business Officer | Sell | −1,347 | −$121.23K |
| 2026-04-16 | Bruce Booth | Director | MIXED | −3,135 | −$764.37K |
| 2026-04-16 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | −$364.16K |
| 2026-04-10 | Noah Goodman | Chief Business Officer | MIXED | −7,764 | −$845.16K |
| 2026-04-01 | Elena Ridloff | Director | MIXED | — | −$854.50K |
| 2026-04-01 | Jeremy G Chadwick | Chief Operating Officer | MIXED | — | −$1.24M |
| 2026-03-25 | Jeremy G Chadwick | Chief Operating Officer | MIXED | −6,850 | −$5.81M |
| 2026-03-20 | Pamela Esposito | Director | MIXED | — | −$75.13K |
| 2026-03-11 | Jeremy G Chadwick | Chief Operating Officer | MIXED | −5,758 | −$1.28M |
| 2026-03-04 | Nello Mainolfi | Chief Executive Officer | A | +215,000 deriv. | — |
| 2026-03-04 | Noah Goodman | Chief Business Officer | A | +9,225 | — |
| 2026-03-04 | Bruce Booth | Director | Sell | −81,866 | −$7.38M |
| 2026-03-04 | Brian Adams | Chief Legal Officer | A | +4,125 | — |
| 2026-03-04 | Jared Gollob | Chief Medical Officer | MIXED | +7,142 | −$916.67K |
| 2026-03-04 | Jeremy G Chadwick | Chief Operating Officer | MIXED | +6,617 | −$515.59K |
| 2026-03-04 | Bruce N. Jacobs | Chief Financial Officer | MIXED | +5,179 | −$1.09M |
| 2026-02-25 | Nello Mainolfi | Chief Executive Officer | MIXED | — | −$2.65M |
| 2026-02-20 | Pamela Esposito | Director | MIXED | — | −$95.52K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Baker Brothers Life Sciences LP | Director | 7,955,916 | $833.62M |
| BIOTECHNOLOGY VALUE FUND II LP | Director | 1,671,048 | $175.09M |
| Nello Mainolfi | Chief Executive Officer | 666,568 | $69.84M |
| BAKER BROS. ADVISORS LP | Director | 534,134 | $55.97M |
| BVF II GP LLC | Director | 484,057 | $50.72M |
| Bruce Booth | Director | 475,805 | $49.85M |
| BVF PARTNERS L P/IL | Director | 353,412 | $37.03M |
| Bruce N. Jacobs | Chief Financial Officer | 320,492 | $33.58M |
| Jared Gollob | Chief Medical Officer | 117,581 | $12.32M |
| Ellen Chiniara | Chief Legal Officer | 80,085 | $8.39M |
| Brian Adams | Chief Legal Officer | 55,416 | $5.81M |
| Jeremy G Chadwick | Chief Operating Officer | 48,297 | $5.06M |
| Noah Goodman | Chief Business Officer | 47,179 | $4.94M |
| Terence Rooney | Chief Medical Officer | 38,000 | $3.98M |
| Elena Ridloff | Director | 3,000 | $314.34K |
| Pamela Esposito | Director | 1,000 | $104.78K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the KYMR quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.